bullish
Belite Bio (BLTE US): Lead Drug Candidate Tapping into Niche Market with Massive Opportunity
395 Views20 Jun 2022 09:45
SUMMARY
- Belite Bio (BLTE US) shares jumped 383% from its IPO price of $6 (announced in late April). Its lead candidate LBS-008 is in clinical trial for currently untreatable eye diseases.
- LBS-008 continues to be well-tolerated. Interim safety and preliminary efficacy data from ongoing two-year phase 2 trial remained positive in Stargardt disease.
- Belite is well-funded to commercialize its pipeline. With the progression of the clinical trial and more data readouts, we believe further stream is left in Belite Bio’s share price.
Related Insights
More »Trending Collections
More »Trending Insights
More »- BYD (1211 HK): God's Eye & Potential HSTECH Index Inclusion
- T&D Holdings (8795) - A Really Good Look (Divs Up, Big Buyback, Good Historical Stats)
- Fat Inheritance Taxes for Hanwha Group Chairman Kim's Three Sons Post Receiving Hanwha Corp Shares
- FnGuide Semiconductor Top10 Index Rebalance Preview: Just One Change Likely
- Skyworth Group (751 HK)'s Latest Partial Buyback. Thoughts On Proration
Top Unpaywalled Insights
More »- The Toyota Way Is Not to Rush, but to Gain a Foothold and Proceed with Caution
- [IO Technicals Weekly 2025/13]: Bullish Momentum Builds as IV Eases
- Aiming for REITs with Lower Downside Risk and Expectations of Higher Shareholder Returns?
- Tariffs, Tapering, and Tectonic Shifts: Markets Brace for April | The New Barbarians #013
- APL Apollo Tubes (APAT IN) Stepping up the Gas on Capacity Expansions
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Belite Bio (BLTE US): Lead Drug Candidate Tapping into Niche Market with Massive Opportunity20 Jun 2022
x